Imperial College London
Alternate

ProfessorMichaelSeckl

Faculty of Medicine, Department of Surgery & Cancer

Professor of Molecular Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 3311 1421m.seckl

 
 
//

Location

 

08Cyclotron buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Seckl:2017:10.1200/JCO.2016.69.7391,
author = {Seckl, MJ and Ottensmeier, CH and Cullen, M and Schmid, P and Ngai, Y and Muthukumar, D and Thompson, J and Harden, S and Middleton, G and Fife, KM and Crosse, B and Taylor, P and Nash, S and Hackshaw, A},
doi = {10.1200/JCO.2016.69.7391},
journal = {Journal of Clinical Oncology},
pages = {1506--1514},
title = {Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)},
url = {http://dx.doi.org/10.1200/JCO.2016.69.7391},
volume = {35},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PurposeTreating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies showthat statins exert additive effects with agents, such as cisplatin, to impair tumor growth, andobservational studies suggest that statins combined with anticancer therapies delay relapse andprolong life in several cancer types. To our knowledge, we report the first large, randomized,placebo-controlled, double-blind trial of a statin with standard-of-care for patients with cancer,specifically SCLC.Patients and MethodsPatients with confirmed SCLC (limited or extensive disease) and performance status 0 to 3 wererandomly assigned to receive daily pravastatin 40 mg or placebo, combined with up to six cycles ofetoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or intolerabletoxicity. Primary end point was overall survival (OS), and secondary end points were progressionfreesurvival (PFS), response rate, and toxicity.ResultsEight hundred forty-six patients from 91 United Kingdom hospitals were recruited. The median ageof recruited patients was 64 years of age, 43% had limited disease, and 57% had extensive disease.There were 758 deaths and 787 PFS events. No benefit was found for pravastatin, either in allpatients or in several subgroups. For pravastatin versus placebo, the 2-year OS rate was 13.2%(95% CI, 10.0 to 16.7) versus 14.1% (95% CI, 10.9 to 17.7), respectively, with a hazard ratio of 1.01(95% CI, 0.88 to 1.16; P = .90. The median OS was 10.7 months v 10.6 months, respectively. Themedian PFS was 7.7 months v 7.3 months, respectively. The median OS (pravastatin v placebo) was14.6 months in both groups for limited disease and 9.1 months versus 8.8 months, respectively, forextensive disease. Adverse events were similar between groups.ConclusionPravastatin 40 mg combined with standard SCLC therapy, although safe, does not benefit patients.Our conclusions are the same as those found in all four much smaller, randomized, placebocontrolledtr
AU  - Seckl,MJ
AU  - Ottensmeier,CH
AU  - Cullen,M
AU  - Schmid,P
AU  - Ngai,Y
AU  - Muthukumar,D
AU  - Thompson,J
AU  - Harden,S
AU  - Middleton,G
AU  - Fife,KM
AU  - Crosse,B
AU  - Taylor,P
AU  - Nash,S
AU  - Hackshaw,A
DO  - 10.1200/JCO.2016.69.7391
EP  - 1514
PY  - 2017///
SN  - 0732-183X
SP  - 1506
TI  - Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)
T2  - Journal of Clinical Oncology
UR  - http://dx.doi.org/10.1200/JCO.2016.69.7391
UR  - https://ascopubs.org/doi/figure/10.1200/JCO.2016.69.7391
UR  - http://hdl.handle.net/10044/1/54190
VL  - 35
ER  -
Download